Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC

NCT07403136 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Vebrekotuzumab
DRUG: PD-1 antibody

Sponsor

Fudan University